Quantum-Si Reports Growth and Strategic Developments

Quantum-Si Incorporated ( (QSI) ) has released its Q2 earnings. Here is a breakdown of the information Quantum-Si Incorporated presented to its investors.

Quantum-Si Incorporated, a leader in proteomics technology, is revolutionizing protein analysis with its single-molecule detection platform. The company recently announced its second quarter 2025 financial results, highlighting significant developments in product offerings and financial performance.

Quantum-Si reported a 33% increase in revenue for the first half of 2025 compared to the same period in 2024, achieving $1.4 million in revenue. The company has expanded its instrument acquisition options to address current capital purchasing challenges and has successfully raised $50 million in capital, extending its cash runway into the second quarter of 2028. Key product developments include the Proteus platform and upcoming launches of the v4 Sequencing Kit and v3 Library Preparation Kit.

Despite facing challenges due to NIH funding issues, Quantum-Si remains committed to its growth strategy. The company recorded a net loss of $28.8 million for the second quarter of 2025, an increase from the previous year’s loss. However, the adjusted EBITDA showed a slight improvement, indicating effective cost management. Operating expenses were tightly controlled, with significant investments in R&D and commercialization efforts.

Looking ahead, Quantum-Si is optimistic about its long-term prospects in the proteomics market. The company is focused on executing its technology roadmap and anticipates providing further updates at its Investor and Analyst Day in November 2025. With a strong capital position and ongoing product development, Quantum-Si is well-positioned to capitalize on future opportunities in the industry.